Alzheimer’s Rethink: Biomarkers, Not Symptoms, to Guide Research

It’s time for researchers to change how they think about Alzheimer’s disease (AD), says a panel of scientists convened by the National Institute on Aging (NIA). The panel proposes that for research purposes, AD should be defined according to a biomarker-based framework instead of the disease’s clinical consequences. A biomarker-based framework, the panel suggests, would give researchers a common language to use in clinical trials, enable a more accurate understanding of the eve